Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! 

China Clinical Trials 2017

Analysis of IND and NDA applications and approvals in China 2011-2017

Download free report on life science investment in China

The Week in Review: WuXi AppTec and MedImmune Start Joint Venture

publication date: Sep 15, 2012
author/source: Richard Daverman, PhD
Deals and Financings

WuXi AppTec (NYSE: WX) has formed a drug development JV with MedImmune, the biologics subsidiary of AstraZeneca (NYSE: AZN) (see story). The JV will own China rights to MEDI5117, a novel monoclonal antibody that is being developed to treat rheumatoid arthritis along with other autoimmune and inflammatory diseases. WuXi will be paid for its development services, while MedImmune will receive payments when the drug achieves milestones. AstraZeneca has the right to buy back China commercialization rights for the drug. If it chooses not to do so, the JV will commercialize the drug in China.

3SBio (NSDQ: SSRX), a China biotech, received an offer to take the company private at a price of $15 per share, a transaction that values the company at $337 million (see story). The offer was made by Dr. Jing Lou, 3SBio’s Chairman and CEO, along with CPEChina Fund LP, a Cayman Island entity associated with CITIC Private Equity Fund. The offer was priced at a 32% premium to yesterday’s closing price of $11.39. In today’s trading, 3SBio rose $1.84 to $13.43, a 16% increase. Even at the buyout price, 3SBio has a lot of value.

Two high-visibility generic drug JVs between east and west pharmas have commenced operations in China. Hisun Pharma (SHE: 600267) and Pfizer (NYSE: PFE) have established their $295 million JV to produce branded generic drugs. At the same time, Merck (NYSE: MRK) and Simcere (NYSE SCR) teamed up to concentrate on generic drugs for chronic ailments, especially cardiovascular and metabolic disease (see story). Both were announced as letters of intent just over a year ago, and now they have become operational.

Qiagen (NSDQ: QGEN), the Dutch medical device company, has teamed up with Lepu Medical Technology (Beijing) (SHE: 300003). The two companies will combine their diagnostic devices, which Lepu will then market in China (see story). The two devices are Qiagen's ESEQuant Lateral Flow System, a test reader, and Lepu's cardiac marker tests that diagnose acute myocardial infarction. Lepu will market the combination under the name Lepu Quant-Gold.

Trials and Approvals

Generon (Shanghai) Corporation has started a clinical trial for the second of its biologic drugs to begin human testing. The anti-inflammatory drug, known as F-652, will enter a Phase I trial in Australia (see story). F-652 is a recombinant protein containing a human interleukin-22 (IL-22) dimer. According to Generon, F-652 is a first-in-class drug candidate, while the company’s other three molecules under development aim for best-in-class status. Generon believes that F-652 will ultimately address unmet medical needs in several inflammatory diseases.

Disclosure: none.


Share this with colleagues:


ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Events
The 9th China Healthcare Investment Conference
Shanghai, China
March 27-29, 2018
Use chinabio18 for 20% discount